The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of BCMA CAR-TS103 in the treatment of refractory, generalized myasthenia gravis. The study is a dose escalation trial in adult, refractory, systemic MG patients. A total of 6-24 MG patients who meet the inclusion criteria are expected to be recruited.